Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Significant Positive Shift in the Glioma Market with 13% CAGR During the Study Period (2019-2032) Expected by Analysts at DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

01 May, 2023, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

The dynamics of the glioma market are anticipated to change in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage by key players, such as Bayer, VBL Therapeutics, Candel Therapeutics, AstraZeneca, DNAtrix, DelMar Pharmaceuticals, Chimerix, KaryoPharma, VBI Vaccines, Kazia Therapeutics, and others

LAS VEGAS, May 1, 2023 /PRNewswire/ -- DelveInsight's Glioma Market Insights report includes a comprehensive understanding of current treatment practices, glioma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Glioma Market Report

  • As per DelveInsight analysis, the glioma market size in the 7MM was approximately USD 1 billion  in 2022.
  • According to the assessment done by DelveInsight, the estimated total incident glioma cases in the 7MM were approximately 47K in 2022. 
  • Leading glioma companies such as Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, VBI Vaccines, TME Pharma, Day One Biopharmaceuticals, Servier, Orbus Therapeutics, TVAX Biomedical, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Forma Therapeutics, Hoffmann-La Roche, Incyte Corporation, Eli Lilly, and others are developing novel glioma drugs that can be available in the glioma market in the coming years.
  • The promising glioma therapies in the pipeline include Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12 (Olaptesed Pegol), Tovorafenib (DAY101), Vorasidenib (AG-881), Eflornithine, TVI-Brain-1, AB-218, BGB-290, Mirdametinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, Cobimetinib, PEMAZYRE (Pemigatinib), VERZENIO (abemaciclib), and others.
  • In December 2022, Chimerix announced the successful launch of the ONC201 Phase III ACTION study in patients with H3 K27M-mutant glioma.
  • In June 2022, Day One Biopharmaceuticals announced positive initial data from its pivotal Phase II (FIREFLY-1) study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG).

Discover which therapies are expected to grab the major glioma market share @ Glioma Market Report

Glioma Overview

Glioma is the most common kind of glial cell tumor in the central nervous system (CNS). Gliomas are infiltrative tumors that affect the brain tissue surrounding them. Glioblastoma is the most hazardous type of brain tumor, whereas pilocytic astrocytomas are the least dangerous. Previously, diffuse gliomas were classified into subgroups and grades depending on histopathologies, such as diffuse astrocytomas, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. The specific etiology of glioma, like other primary brain tumors, remains unknown. However, certain variables may increase the risk of getting a brain tumor. Glioma symptoms vary depending on tumor type, size, location, and growth rate. Some common glioma symptoms include headache, nausea or vomiting, memory loss, urine incontinence, speech problems, and others. A medical history and a physical examination are used for glioma diagnosis. 

Glioma Epidemiology Segmentation

DelveInsight estimates that there were approximately 47K incident cases of glioma in the 7MM in 2022.

As per our analysis, the United States contributed to the largest incident population of glioma, acquiring ~40% of the 7MM in 2022.

The glioma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total glioma incident cases
  • Glioma grade-specific cases
  • Glioma age-specific cases
  • Glioma type-specific cases

Download the report to understand which factors are driving glioma epidemiology trends @ Glioma Epidemiological Insights

Glioma Treatment Market 

Glioma treatment is based on the type of glioma, its size and location, and the patient's unique characteristics. Chemotherapy and radiation therapy will be administered after surgery, particularly in individuals when the tumor cannot be removed entirely because it has invaded critical parts of the brain or is inaccessible. The typical glioma treatment protocol comprises surgery, chemotherapy, and radiation. Chemotherapy may include carmustine (BCNU), lomustine (CCNU), or gleostine (generic), cisplatin, carboplatin, etoposide, and irinotecan in case of low-grade glioma whereas temozolomide (TEMODAR) is the standard chemotherapy used in case of high-grade glioma majorly, Gliadel wafer implants (biodegradable discs injected with BCNU) are usually given as adjunctive treatment after surgery, although usage of Gliadel wafers remains a point of controversy due to its questionable survival benefits. Avastin (Genentech) and Temodar/Temodal (Merck), among others, are approved medications for HGG. However, due to patent expiration, the generic version of Temodar and biosimilars of Avastin are available on the glioma market. As generics and biosimilars are more cost-effective for patients than new medicines, intense competition exists among them. Furthermore, due to a lack of knowledge concerning bevacizumab's overall survival benefit, it is not recommended in unselected patients with newly diagnosed GBM. Currently, only one medication for LGG is approved, Tafinlar (dabrafenib) plus Mekinist (trametinib).

Moreover, the current therapeutic market lacks a viable method for curing glioblastoma; therefore, the survival rate of people diagnosed with glioma remains poor. Glioma is incurable, and treatment choices are limited. Furthermore, the tumor has a high recurrence rate and a poor patient prognosis. In addition, there is currently no approved therapy for the unmethylated MGMT patient pool. 

To know more about glioma treatment guidelines, visit @ Glioma Management 

Glioma Therapies and Key Companies

  • Regorafenib: Bayer
  • ONC201: Chimerix
  • AV-GBM-1: Aivita Biomedical
  • Enzastaurin (DB-102): Denovo Biopharma
  • DCVax-L: Northwest Therapeutics
  • Ofranergene Obadenovec (VB-111): VBL Therapeutics
  • LAM561 (2-OHOA): Laminar Pharmaceuticals
  • MEDI4736 (durvalumab): MedImmune
  • Tasadenoturev (DNX-2401): DNAtrix
  • ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
  • IGV-001: Imvax
  • SurVaxM: MimiVax
  • Berubicin: CNS Pharmaceuticals
  • GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)
  • Lerapolturev + Pembrolizumab: Istari Oncology
  • SONALA-001 + Exablate 2.0 Device: SonALAsense
  • VAL-083 (dianhydrogalactitol): Kintara Therapeutics
  • Pomalidomide: Bristol Myers Squibb
  • MDNA55: Medicenna Therapeutics
  • BMX-001: BioMimetix
  • Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme
  • Paxalisib (GDC-0084): Kazia Therapeutics
  • OKN-007: Oblato
  • Temferon: Genenta Science
  • EO2401: Enterome
  • INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals
  • Selinexor (KPT-330): Karyopharm Therapeutics
  • VBI-1901: VBI Vaccines
  • NOX-A12 (Olaptesed Pegol): TME Pharma
  • Tovorafenib (DAY101): Day One Biopharmaceuticals
  • Vorasidenib (AG-881): Servier
  • Eflornithine: Orbus Therapeutics
  • TVI-Brain-1: TVAX Biomedical
  • AB-218: AnHeart Therapeutics
  • BGB-290: Beigene
  • Mirdametinib: SpringWorks Therapeutics
  • FT-2102 (Olutasidenib): Forma Therapeutics
  • Vinblastine + Bevacizumab: Hoffmann-La Roche
  • Cobimetinib: Hoffmann-La Roche
  • PEMAZYRE (Pemigatinib): Incyte Corporation
  • VERZENIO (abemaciclib): Eli Lilly

Learn more about the FDA-approved drugs for glioma @ Drugs for Glioma Treatment 

Glioma Market Dynamics

Glioma market growth can be ascribed to various factors, including an aging population, evolving research, better diagnostic tests, developing surgical procedures, improved radiotherapy techniques, and novel systemic medicines.

Commercially, there is a greater emphasis on high-grade glioma than low-grade glioma because patients with low-grade glioma often live longer than those with high-grade glioma. As a result, just a few therapies are in late-stage studies, while the majority are in early-stage trials. In the case of GBM, on the other hand, the pipeline is robust, with numerous potential therapies in late and mid-stage research that have yet to be marketed. The pipeline includes drugs with varied modes of action and administration routes. It is interesting to note that the emerging market of glioma includes budding gene therapy, i.e., ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively, and these therapies are going to alter the glioma market dynamics in the upcoming years.

The current glioma market has been categorized based on the dominant treatment pattern across the 7MM, which shows slight variances in the overall prescription pattern. The forecast model considers surgery, chemotherapy/radiation therapy, bevacizumab + radiotherapy/chemotherapy, and OPTUNE with temozolomide. The anticipated launch of new therapies and improved integration of early patient screening, medication in secondary care and other clinical settings, research on optimum implementation methods, and increased awareness may eventually facilitate the development of successful treatment alternatives. 

However, there are a few challenges to the timely identification and treatment of these patients, such as a lack of a reliable biomarker that can aid in diagnosis and patient classification and identifying recurrence and signaling medication response. Furthermore, the failure rate of high-phased drug trials is significant, making it impossible to predict trial success, exacerbating the need for medicines that could assist ease the patient segment with this severe kind of cancer.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]

Base Year

2019

Glioma Market CAGR

Approx.13%

Glioma Market Size in 2022

USD 1,000 million

Key Glioma Companies

Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai and Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, VBI Vaccines, TME Pharma, Day One Biopharmaceuticals, Servier, Orbus Therapeutics, TVAX Biomedical, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Forma Therapeutics, Hoffmann-La Roche, Incyte Corporation, Eli Lilly, and others

Key Pipeline Glioma Therapies

Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12 (Olaptesed Pegol), Tovorafenib (DAY101), Vorasidenib (AG-881), Eflornithine, TVI-Brain-1, AB-218, BGB-290, Mirdametinib, FT-2102 (Olutasidenib), Vinblastine + Bevacizumab, Cobimetinib, PEMAZYRE (Pemigatinib), VERZENIO (abemaciclib), and others

Scope of the Glioma Market Report

  • Therapeutic Assessment: Glioma current marketed and emerging therapies
  • Glioma Market Dynamics: Conjoint Analysis of Emerging Glioma Drugs 
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's Views, Analyst's Views, Glioma Market Access and Reimbursement

Discover more about glioma drugs in development @ Glioma Clinical Trials

Table to Contents

1

Key Insights

2

Report Introduction

3

Executive Summary

4

Key Events

5

Epidemiology and Market Forecast Methodology

6

Glioma Market Overview at a Glance

6.1

Market Share (%) Distribution of Glioma by Therapies in 2022

6.2

Market Share (%) Distribution of Glioma by Therapies in 2032

7

Disease Background and Overview: Gliomas

7.1

Introduction

7.2

Classification of gliomas

7.2.1

Low-grade Gliomas

7.2.2

High-grade Gliomas

7.3

Signs and symptoms

7.4

Causes

7.5

Diagnosis

7.5.1

Neurological exams

7.5.2

Angiograms

7.5.3

Computerized tomography (CT)

7.5.4

Magnetic resonance imaging (MRI)

7.5.5

Perfusion MRI

7.5.6

MR spectroscopy

7.5.7

Histological diagnosis

7.5.8

Surgical biopsy

8

Treatment and management

8.1

Treatment of LGGs

8.2

Treatment of HGGs

8.3

Symptom management

8.4

Treatment guidelines and recommendations

8.4.1

American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma (2017)

8.4.2

American Society of Therapeutic Radiology and Oncology (ASTRO) Clinical Practice Guideline for LGGs (2021)

8.4.3

National Comprehensive Cancer Network [NCCN] Guidelines for the Management of Gliomas (2022)

8.4.4

National Institute for Health and Care Excellence Guidelines for the Management of Newly Diagnosed Glioblastoma (2021)

8.4.5

Japanese Society of Neurological Surgery Guidelines for the Treatment of Adult Glioblastoma (2019)

8.4.6

Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions for Glioblastoma in Adults (2020)

8.4.7

Clinical Recommendation for Glioblastoma (Associazione Italiana di Oncologia Medica [AIOM], 2021)

8.4.8

Medical Oncology Spanish Society (SEOM) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma

8.4.9

European Association of Neuro-Oncology (EANO) Guidelines for the Diagnosis and Management of Adult Patients with Diffuse Gliomas (2021)

8.4.10

SEOM Guideline Recommendations for LGGs (2017)

9

Epidemiology and Patient Population of Glioma in the 7MM

9.1

Key Findings

9.2

Assumptions and Rationale

9.3

Total Incident Cases of Glioma in the 7MM

9.4

The United States

9.4.1

Total Incident Cases of Glioma in the United States

9.4.2

Grade-specific Cases of Glioma in the United States

9.4.3

Age-specific Cases of Glioma in the United States

9.4.4

Type-specific Cases of Glioma in the United States

9.5

EU4 and the UK

9.5.1

Total Incident Cases of Glioma in EU4 and the UK

9.5.2

Grade-specific Cases of Glioma in EU4 and the UK

9.5.3

Age-specific Cases of Glioma in EU4 and the UK

9.5.4

Type-specific Cases of Glioma in EU4 and the UK

9.6

Japan

9.6.1

Total Incident Cases of Glioma in Japan

9.6.2

Grade-specific Cases of Glioma in Japan

9.6.3

Age-specific Cases of Glioma in Japan

9.6.4

Type-specific cases of Glioma in Japan

10

Patient Journey

11

Key Endpoints in Glioma

12

Marketed Products

12.1

Key Competitors

12.2

OPTUNE: Novocure Limited

12.2.1

Product description

12.2.2

Regulatory milestones

12.2.3

Other developmental activities

12.2.4

Current pipeline activity

12.2.5

Safety and efficacy

12.2.6

Product profile

12.3

AVASTIN (bevacizumab): Genentech

12.3.1

Product description

12.3.2

Regulatory milestones

12.3.3

Other developmental activities

12.3.4

Safety and efficacy

12.3.5

Product profile

12.4

TEMODAR (temozolomide): Merck

12.4.1

Product description

12.4.2

Regulatory milestones

12.4.3

Other development activities

12.4.4

Current pipeline activity

12.4.5

Safety and efficacy

12.4.6

Product profile

12.5

DELYTACT: Daiichi Sankyo

12.5.1

Product description

12.5.2

Regulatory milestones

12.5.3

Other developmental activities

12.5.4

Safety and efficacy

12.5.5

Product profile

12.6

TAFINLAR (dabrafenib) + MEKINIST (trametinib): Novartis

12.6.1

Product description

12.6.2

Regulatory milestones

12.6.3

Other Developmental Activities

12.6.4

Clinical development

12.6.5

Safety and efficacy

12.6.6

Product profile

13

Emerging Drugs

13.1

Key Competitors

13.2

Regorafenib: Bayer

13.2.1

Product description

13.2.2

Other developmental activities

13.2.3

Clinical development

13.2.4

Safety and efficacy

13.3

ONC201: Chimerix

13.3.1

Product description

13.3.2

Other developmental activities

13.3.3

Clinical development

13.3.4

Safety and efficacy

13.4

AV-GBM-1: Aivita Biomedical

13.4.1

Product description

13.4.2

Clinical development

13.4.3

Safety and efficacy

13.5

Enzastaurin (DB-102): Denovo Biopharma

13.5.1

Product description

13.5.2

Other developmental activities

13.5.3

Clinical development

13.5.4

Safety and efficacy

13.6

DCVax-L: Northwest Therapeutics

13.6.1

Product description

13.6.2

Other developmental activity

13.6.3

Clinical development

13.6.4

Safety and efficacy

13.7

Ofranergene Obadenovec (VB-111): VBL Therapeutics

13.7.1

Product Description

13.7.2

Other Developmental Activities

13.7.3

Clinical development

13.7.4

Safety and efficacy

13.8

LAM561 (2-OHOA): Laminar Pharmaceuticals

13.8.1

Product description

13.8.2

Other developmental activities

13.8.3

Clinical development

13.8.4

Safety and efficacy

13.9

MEDI4736 (durvalumab): MedImmune

13.9.1

Product description

13.9.2

Clinical Development

13.9.3

Safety and efficacy

13.1

Tasadenoturev (DNX-2401): DNAtrix

13.10.1

Product description

13.10.2

Other developmental activities

13.10.3

Clinical development

13.10.4

Safety and efficacy

13.11

ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

13.11.1

Product description

13.11.2

Other developmental activities

13.11.3

Clinical development

13.11.4

Safety and efficacy

13.12

IGV-001: Imvax

13.12.1

Product description

13.12.2

Other developmental activities

13.12.3

Clinical development

13.12.4

Safety and efficacy

13.13

SurVaxM: MimiVax

13.13.1

Product description

13.13.2

Other developmental activities

13.13.3

Clinical development

13.13.4

Safety and efficacy

13.14

Berubicin: CNS Pharmaceuticals

13.14.1

Product description

13.14.2

Other developmental activities

13.14.3

Clinical development

13.14.4

Safety and efficacy

13.15

GLIOVAC (Sitoiganap): Epitopoietic Research Corporation (ERC)

13.15.1

Product description

13.15.2

Other developmental activities

13.15.3

Clinical development

13.15.4

Safety and efficacy

13.16

Lerapolturev + Pembrolizumab: Istari Oncology

13.16.1

Product description

13.16.2

Other developmental activities

13.16.3

Clinical development

13.16.4

Safety and efficacy

13.17

SONALA-001 + Exablate 2.0 Device: SonALAsense

13.17.1

Product description

13.17.2

Clinical development

13.17.3

Safety and efficacy

13.18

VAL-083 (dianhydrogalactitol): Kintara Therapeutics

13.18.1

Product description

13.18.2

Other developmental activities

13.18.3

Clinical development

13.18.4

Safety and efficacy

13.19

Pomalidomide: Bristol Myers Squibb

13.19.1

Product description

13.19.2

Other developmental activities

13.19.3

Clinical development

13.19.4

Safety and efficacy

13.2

MDNA55: Medicenna Therapeutics

13.20.1

Product description

13.20.2

Other developmental activities

13.20.3

Clinical development

13.20.4

Safety and efficacy

13.21

BMX-001: BioMimetix

13.21.1

Product description

13.21.2

Other developmental activity

13.21.3

Clinical development

13.21.4

Safety and efficacy

13.22

Lenvatinib ± Pembrolizumab: Eisai and Merck Sharp & Dohme

13.22.1

Product description

13.22.2

Clinical development

13.22.3

Safety and efficacy

13.23

Paxalisib (GDC-0084): Kazia Therapeutics

13.23.1

Product description

13.23.2

Other developmental activities

13.23.3

Clinical development

13.23.4

Safety and efficacy

13.24

OKN-007: Oblato

13.24.1

Product description

13.24.2

Other developmental Activity

13.24.3

Clinical development

13.24.4

Safety and efficacy

13.25

Temferon: Genenta Science

13.25.1

Product description

13.25.2

Clinical development

13.25.3

Safety and efficacy

13.26

EO2401: Enterome

13.26.1

Product description

13.26.2

Clinical development

13.26.3

Safety and efficacy

13.27

INO-5401+ INO-9012+ LIBTAYO (cemiplimab): Inovio Pharmaceuticals

13.27.1

Product description

13.27.2

Clinical development

13.27.3

Safety and efficacy

13.28

Selinexor (KPT-330): Karyopharm Therapeutics

13.28.1

Product description

13.28.2

Clinical development

13.28.3

Safety and efficacy

13.29

Olutasidenib (FT-2102): Forma Therapeutics

13.29.1

Product description

13.29.2

Other developmental activities

13.29.3

Clinical development

13.29.4

Safety and efficacy

13.3

VBI-1901: VBI Vaccines

13.30.1

Product description

13.30.2

Other developmental activities

13.30.3

Clinical development

13.30.4

Safety and efficacy

13.31

NOX-A12 (Olaptesed Pegol): TME Pharma

13.31.1

Product description

13.31.2

Other developmental activities

13.31.3

Clinical development

13.31.4

Safety and efficacy

13.32

Tovorafenib (DAY101): Day One Biopharmaceuticals

13.32.1

Product description

13.32.2

Other developmental activities

13.32.3

Clinical development

13.32.4

Safety and efficacy

13.33

Vorasidenib (AG-881): Servier

13.33.1

Product description

13.33.2

Other developmental activities

13.33.3

Clinical development

13.33.4

Safety and efficacy

13.34

Eflornithine: Orbus Therapeutics

13.34.1

Product description

13.34.2

Other developmental activities

13.34.3

Clinical development

13.34.4

Safety and efficacy

13.35

TVI-Brain-1: TVAX Biomedical

13.35.1

Product description

13.35.2

Other developmental activities

13.35.3

Clinical development

13.36

AB-218: AnHeart Therapeutics

13.36.1

Product description

13.36.2

Other developmental activities

13.36.3

Clinical development

13.36.4

Safety and efficacy

13.37

BGB-290: Beigene

13.37.1

Product description

13.37.2

Clinical development

13.37.3

Safety and efficacy

13.38

Mirdametinib: SpringWorks Therapeutics

13.38.1

Product description

13.38.2

Other developmental activities

13.38.3

Clinical development

13.38.4

Safety and efficacy

13.39

Vinblastine + Bevacizumab: Hoffmann-La Roche

13.39.1

Product description

13.39.2

Clinical development

13.39.3

Safety and efficacy

13.4

Cobimetinib: Hoffmann-La Roche

13.40.1

Product description

13.40.2

Clinical development

13.40.3

Safety and efficacy

13.41

PEMAZYRE (Pemigatinib): Incyte Corporation

13.41.1

Product description

13.41.2

Clinical development

13.42

VERZENIO (abemaciclib): Eli Lilly

13.42.1

Product description

13.42.2

Clinical development

13.42.3

Safety and efficacy

14

Glioma: Seven Major Market Analysis

14.1

Key Findings

14.2

Market Outlook

14.3

Key Market Forecast Assumptions

14.4

Conjoint Analysis

14.5

Total Market Size of Glioma in the 7MM

14.6

United States Market Size

14.6.1

Total Market size of Glioma in the United States

14.6.2

Market Size of Glioma by Current and Emerging Therapies in the United States

14.7

EU4 and UK Market Size

14.7.1

Total Market size of Glioma in EU4 and the UK

14.7.2

Market Size of Glioma by Current and Emerging Therapies in EU4 and the UK

14.8

Japan Market Size

14.8.1

Total Market size of Glioma in Japan

14.8.2

Market Size of Glioma by Current and Emerging Therapies in Japan

15

Unmet Needs

16

SWOT Analysis

17

KOL Views

18

Market Access and Reimbursement for Glioma

18.1

United States

18.2

Europe

18.3

Japan

19

Appendix

19.1

Bibliography

19.2

Report Methodology

20

DelveInsight Capabilities

21

Disclaimer

22

About DelveInsight

Related Reports

Glioma Epidemiology Forecast

Glioma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted glioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Glioma Pipeline

Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioma companies, including PTC Therapeutics, Ono Pharmaceuticals, Philogen, SpringWorks Therapeutics, Xennials Therapeutics, AnHeart Therapeutics, Istari Oncology, among others.

High-Grade Glioma Pipeline

High-Grade Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key high-grade glioma companies, including PTC Therapeutics, Aadi, Lee's Pharmaceutical, among others.

Malignant Glioma Pipeline

Malignant Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key malignant glioma companies, including Bexion Pharmaceuticals, Inc., Lee's Pharmaceutical Limited, Merck & Co, Oblato, Inc., OncoSynergy, Inc, among others.

Recurrent Malignant Glioma Pipeline

Recurrent Malignant Glioma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent malignant glioma companies, including Bexion Pharmaceuticals, Inc., Merck, Oblato, OncoSynergy, Inc, among others.

Glioblastoma Pipeline

Glioblastoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glioblastoma companies, including AstraZeneca, BioNTech, Merck, Pfizer, Roche, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us
Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

DelveInsight's GPRC5D-directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

Sleep Apnea Market to Accelerate Substantially at a CAGR of 20% During the Study Period (2020-2034) | DelveInsight

DelveInsight's Sleep Apnea Market Insights report includes a comprehensive understanding of current treatment practices, sleep apnea emerging drugs,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.